Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks

Authors

Barry Hendin, Phoenix Neurological Associates
Robert T. Naismith, Washington University School of Medicine in St. Louis
Sibyl E. Wray, Hope Neurology MS Center
Deren Huang, Mount Carmel Neuroscience and MDH Research
Qunming Dong, Biogen
Terrie Livingston, Biogen
Daniel L. Jones, Biogen
Crystal Watson, Biogen
Mehul Jhaveri, Biogen

Journal

Patient Preference and Adherence

Publication Date

2018

Volume

2018

Issue

12

Inclusive Pages

1289—1297

Document Type

Open Access Publication

DOI

10.2147/PPA.S157317

Rights and Permissions

Hendin B, Naismith RT, Wray SE, Huang D, Dong Q, Livingston T, Jones DL, Watson C, Jhaveri M. 2018. Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks. Patient Preference and Adherence. 2018(12): 1289—1297. https://doi.org/10.2147/PPA.S157317.

Recommended Citation

Hendin, Barry; Naismith, Robert T.; Wray, Sibyl E.; Huang, Deren; Dong, Qunming; Livingston, Terrie; Jones, Daniel L.; Watson, Crystal; and Jhaveri, Mehul, "Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks." Patient Preference and Adherence. 2018, 12. 1289—1297. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/7216